Lv1
98 积分 2026-01-18 加入
Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability
10天前
已完结
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
10天前
已完结
Bimekizumab versus Secukinumab in Plaque Psoriasis
16天前
已完结
Bimekizumab versus Adalimumab in Plaque Psoriasis
16天前
已完结
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
16天前
已完结
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
16天前
已完结
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)
1个月前
已完结
Mapping Dermatology Life Quality Index with EQ-5D health utility index score in Chinese patients with moderate to severe psoriasis
1个月前
已关闭
A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis
1个月前
已完结
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial
1个月前
已关闭
皖公网安备34019202002308
